AKU:NSD-Akumin Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 1.02

Change

+0.01 (+0.99)%

Market Cap

USD 0.09B

Volume

0.04M

Avg Analyst Target

USD 1.75 (+71.57%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

AKU Stock Forecast & Price:
Based on the Akumin Inc stock forecasts from 2 analysts, the average analyst target price for Akumin Inc is USD 1.75 over the next 12 months. Akumin Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Akumin Inc is Slightly Bearish, which is based on 6 positive signals and 9 negative signals. At the last closing, Akumin Inc’s stock price was USD 1.02. Akumin Inc’s stock price has changed by +2.93% over the past week, -43.02% over the past month and -35.44% over the last year.

About Akumin Inc (AKU:NSD)

Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuc ...Read More

Company Website : https://www.akumin.com

Address : 8300 West Sunrise Boulevard, Plantation, FL, United States, 33322

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.94

52 Week High : 2.31

Short Ratio : 8.88

52 Week Low : 0.46

Shorted Shares : 275,121

200 Day Moving Average : 1.14

Shorted Shares Previous Month : 264,255

50 Day Moving Average : 1.67

Shares Held By Insiders : 35.93%

Short Percentage : 0.58%

Shares Held by Institutions : 29.79%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-29 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina Inc

-8.34 (-3.84%)

 USD34.45B 49.32 -9.92
IDXX IDEXX Laboratories Inc

+8.86 (+2.21%)

 USD34.07B 51.81 36.51
ICLR ICON PLC

-2.76 (-1.29%)

 USD17.88B 37.76 18.17
PRAH PRA Health Sciences, Inc

N/A

 USD10.70B 50.52 25.79
EXAS EXACT Sciences Corporation

-0.31 (-0.75%)

 USD7.58B N/A -18.10
MEDP Medpace Holdings Inc

-5.41 (-2.54%)

 USD6.75B 34.01 24.57
GH Guardant Health Inc

-1.60 (-3.13%)

 USD5.28B N/A -10.04
NTRA Natera Inc

-0.32 (-0.85%)

 USD4.10B N/A -7.59
NEOG Neogen Corporation

+0.25 (+1.64%)

 USD3.52B 47.85 47.52
SYNH INC Research Holdings Inc

+0.23 (+0.68%)

 USD3.49B 12.30 8.97

ETFs Containing AKU

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -41.71% 72% C- 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -41.71% 72% C- 38% F
Trailing 12 Months  
Capital Gain -33.33% 75% C 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.33% 75% C 43% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -28.01% 20% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.01% 20% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 30.67% 81% B- 54% F
Risk Adjusted Return -91.34% 11% F 5% F
Market Capitalization 0.09B 43% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 72.00 13% F 14% F
Price/Book Ratio 2.80 38% F 30% F
Price / Cash Flow Ratio 5.47 25% F 31% F
EV/EBITDA 17.16 14% F 14% F
Management Effectiveness  
Return on Equity -45.91% 53% F 31% F
Return on Invested Capital 4.30% 79% C+ 66% D
Return on Assets 1.11% 83% B 67% D+
Debt to Equity Ratio 422.17% 3% F 5% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 8.88 12% F 13% F
Short Percent 0.58% 79% C+ 75% C
Beta 0.94 67% D+ 58% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector